Joseph J. Villafranca
President at Biopharmaceutical Consultants LLC
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Richard C. Lufkin | M | 77 |
Anima Cell Metrology, Inc.
 Anima Cell Metrology, Inc. Packaged SoftwareTechnology Services Anima Cell Metrology, Inc. engages in the development of novel technologies to monitor protein synthesis in living cells. The company was founded by Zeev Smilansky and is headquartered in Bernardsville, NJ. | 19 years |
| Theresa Wingrove | M | 66 | 13 years | |
| Joseph J. Kenny | M | - | 15 years | |
| Thomas J. McKearn | M | 75 |
Anima Cell Metrology, Inc.
Anima Cell Metrology, Inc. Packaged SoftwareTechnology Services Anima Cell Metrology, Inc. engages in the development of novel technologies to monitor protein synthesis in living cells. The company was founded by Zeev Smilansky and is headquartered in Bernardsville, NJ. | - |
| Audrey Bergan | F | - | 10 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Daniel Junius | M | 71 | 13 years | |
| David B. Johnston | M | 68 | 5 years | |
| Mitchel Sayare | M | 76 | 25 years | |
| Mark Enyedy | M | 60 | 8 years | |
| Stephen McCluski | M | 72 | 17 years | |
| Howard H. Pien | M | 66 | 9 years | |
| Thomas Ryll | M | 64 | 6 years | |
| Sarah Kiely | F | - | 7 years | |
| Stuart Arbuckle | M | 58 | 6 years | |
| Kristine Peterson | F | 64 | 12 years | |
| Mark Goldberg | M | 69 | 13 years | |
| Suzanne M. Cadden | F | 64 | - | |
| Richard Wallace | M | 72 | 17 years | |
| C. Boyd Clarke | M | 74 |
Neose Technologies, Inc.
 Neose Technologies, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to develop proprietary drugs, focusing primarily on therapeutic proteins. Its technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed. Its proprietary drug development portfolio currently consists of two therapeutic protein candidates.GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and it gives treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Its second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor G-CSF and it is prescribed to stimulate production of neutrophils (a type of white blood cell). Its trademarks are NEOSE, GlycoPEGylation and GlycoConjugation. It operates predominantly in the domestic market. | 5 years |
| Nicole Onetto | M | 71 | 11 years | |
| David Warren Carter | M | 84 | 14 years | |
| Paul Neff | M | 72 |
Neose Technologies, Inc.
Neose Technologies, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to develop proprietary drugs, focusing primarily on therapeutic proteins. Its technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed. Its proprietary drug development portfolio currently consists of two therapeutic protein candidates.GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and it gives treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Its second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor G-CSF and it is prescribed to stimulate production of neutrophils (a type of white blood cell). Its trademarks are NEOSE, GlycoPEGylation and GlycoConjugation. It operates predominantly in the domestic market. | 9 years |
| Craig Barrows | M | 69 | 13 years | |
| Gregory Perry | M | 63 | 4 years | |
| Dean Mitchell | M | 68 | 12 years | |
| Mark B. Skaletsky | M | 75 | 13 years | |
| Leonard Patrick Gage | M | 81 |
Neose Technologies, Inc.
Neose Technologies, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to develop proprietary drugs, focusing primarily on therapeutic proteins. Its technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed. Its proprietary drug development portfolio currently consists of two therapeutic protein candidates.GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and it gives treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Its second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor G-CSF and it is prescribed to stimulate production of neutrophils (a type of white blood cell). Its trademarks are NEOSE, GlycoPEGylation and GlycoConjugation. It operates predominantly in the domestic market. | 8 years |
| Blaine McKee | M | 59 | 1 years | |
| Robert Lutz | M | - | 23 years | |
| Elizabeth Hamilton Seabury Wyatt | M | 76 |
Neose Technologies, Inc.
Neose Technologies, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to develop proprietary drugs, focusing primarily on therapeutic proteins. Its technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed. Its proprietary drug development portfolio currently consists of two therapeutic protein candidates.GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and it gives treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Its second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor G-CSF and it is prescribed to stimulate production of neutrophils (a type of white blood cell). Its trademarks are NEOSE, GlycoPEGylation and GlycoConjugation. It operates predominantly in the domestic market. | - |
| Linda Buono | M | 58 | 8 years | |
| Richard Gregory | M | 66 | 4 years | |
| Sandra E. Poole | F | 60 | 3 years | |
| Ellie Harrison | F | 69 | - | |
| Eric Guempel | M | - | - | |
| James G. Stout | M | 58 | - | |
| Robert I. Kriebel | M | 81 |
Neose Technologies, Inc.
Neose Technologies, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to develop proprietary drugs, focusing primarily on therapeutic proteins. Its technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed. Its proprietary drug development portfolio currently consists of two therapeutic protein candidates.GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and it gives treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Its second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor G-CSF and it is prescribed to stimulate production of neutrophils (a type of white blood cell). Its trademarks are NEOSE, GlycoPEGylation and GlycoConjugation. It operates predominantly in the domestic market. | 3 years |
| Charles Q. Morris | M | 59 | 4 years | |
| Amy Reilly | F | 51 | 2 years | |
| Anna Berkenblit | M | 54 | 8 years | |
| Peter J. Williams | M | 69 | 8 years | |
| James J. O'Leary | M | 60 | 6 years | |
| Rick A. Winegar | M | - |
Tunnell Consulting, Inc.
 Tunnell Consulting, Inc. Miscellaneous Commercial ServicesCommercial Services Tunnell Consulting, Inc. provides technical, organizational and operational consulting services. It provides life sciences technical services, process and organizational excellence services, strategy and supply chain management services. The firm serves in the area of pharmaceutical, government and biotechnology departments. The company was founded in 1962 and is headquartered in King of Prussia, PA. | 9 years |
| Karleen Oberton | F | 54 | 2 years | |
| John Tagliamonte | M | 57 | 1 years | |
| H. Parker | F | 68 |
Neose Technologies, Inc.
Neose Technologies, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to develop proprietary drugs, focusing primarily on therapeutic proteins. Its technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed. Its proprietary drug development portfolio currently consists of two therapeutic protein candidates.GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and it gives treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Its second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor G-CSF and it is prescribed to stimulate production of neutrophils (a type of white blood cell). Its trademarks are NEOSE, GlycoPEGylation and GlycoConjugation. It operates predominantly in the domestic market. | 4 years |
| Brian H. Dovey | M | 83 |
Neose Technologies, Inc.
Neose Technologies, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to develop proprietary drugs, focusing primarily on therapeutic proteins. Its technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed. Its proprietary drug development portfolio currently consists of two therapeutic protein candidates.GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and it gives treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Its second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor G-CSF and it is prescribed to stimulate production of neutrophils (a type of white blood cell). Its trademarks are NEOSE, GlycoPEGylation and GlycoConjugation. It operates predominantly in the domestic market. | 7 years |
| Walter Blättler | M | 75 | 20 years | |
| Benjamin J. del Tito | M | 68 |
Neose Technologies, Inc.
Neose Technologies, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to develop proprietary drugs, focusing primarily on therapeutic proteins. Its technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed. Its proprietary drug development portfolio currently consists of two therapeutic protein candidates.GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and it gives treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Its second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor G-CSF and it is prescribed to stimulate production of neutrophils (a type of white blood cell). Its trademarks are NEOSE, GlycoPEGylation and GlycoConjugation. It operates predominantly in the domestic market. | 2 years |
| Pauline Jen Ryan | F | - | 8 years | |
| Michel Streuli | M | - | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 51 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Joseph J. Villafranca
- Personal Network
